好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurology Clerkship Shelf Score Analysis Pre- and Post-Satisfactory/Unsatisfactory Grading System
好色先生, Research, and Methodology
P4 - Poster Session 4 (8:00 AM-9:00 AM)
15-002

This study examines the effects of changing the clerkship grading system at our institution from a traditional tiered scale to Satisfactory/Unsatisfactory grading. Scores on the National Board of Medical Examiners (NMBE) subject examination in Clinical Neurology are an objective measure that could reflect how changes in the grading system may impact learning. 

Medical schools are continually undergoing innovative changes for curriculum improvement including revision of grading systems. In an attempt to reduce student anxiety and stress, many academic institutions have transitioned from traditional tiered grading to a satisfactory/unsatisfactory grading system. It is unclear what effect this change has had on learning and academic outcomes, specifically, end of clerkship national examinations.

A retrospective analysis was performed on available data two years prior to implementation of the Satisfactory/Unsatisfactory grading system from 2018 to 2020 and two years after from 2020 to 2022. The academic outcomes assessed were first-attempt fail rate, one standard deviation below equated percent correct national means and mean NMBE Clinical Neurology scores per academic year.

The first-attempt fail rate prior to implementation of the satisfactory/unsatisfactory evaluation system was zero, but afterwards the first-attempt fail rate increased to 2.4% in the 2021-2022 academic year. The one standard deviation below equated percent correct national mean score more than doubled between 2018-2019 and 2021-2022 academic years. Full results for mean NMBE score will be available once data collection is complete.

Academic outcomes as measured by shelf exam scores appear to have been adversely affected following adoption of a satisfactory/unsatisfactory grading system. Future analysis will include United States Medical Licensing Examination board certification results to obtain additional objective data.

Authors/Disclosures
Jordan Mayberry, MD (Duke University Medical Center)
PRESENTER
Dr. Mayberry has nothing to disclose.
Vern C. Juel, MD, FAAN (Duke University Medical Center) Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Juel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. The institution of Dr. Juel has received research support from argenx. The institution of Dr. Juel has received research support from Alexion. The institution of Dr. Juel has received research support from Janssen. The institution of Dr. Juel has received research support from NIH Rare Diseases Network.
Karissa Gable, MD, FAAN Dr. Gable has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Accordant. Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Gable has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Takeda. Dr. Gable has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Gable has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazenca. Dr. Gable has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL Behring. Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols . Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for annexon. Dr. Gable has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Gable has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Gable has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx.
No disclosure on file
Christine R. Berry, BS (Duke University Medical Center) Mrs. Berry has nothing to disclose.